Rosiglitazone/Simvastatin

罗格列酮/辛伐他汀

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRosiglitazone/Simvastatin
Drug Alias NameAvandia + statin罗格列酮+辛伐他汀Rosiglitazone and Simvastatin罗格列酮-辛伐他汀Simvastatin/Rosiglitazone +[11] 
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsPeroxisome proliferator-activated receptor γ agonists
TargetsPeroxisome proliferator-activated receptor γHMG-CoA reductase
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Rosiglitazone MaleateSimvastatin
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A